AP NEWS

Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences’ PCT Platform Published in 2018

January 24, 2019
Over 20 Journal Articles Describe the Advantages of the PCT Platform in Multiple Areas of Research, Including Cancer, Biomarker Discovery, and Food SafetySOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (OTCQB:

Over 20 Journal Articles Describe the Advantages of the PCT Platform in Multiple Areas of Research, Including Cancer, Biomarker Discovery, and Food Safety

SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that more than 20 scientific papers citing the advantages of the Company’s pressure cycling technology (“PCT”) platform were published by independent researchers worldwide in 2018. The publications, authored by scientists from academia, government, and industry, described a wide range of enabling applications for PBI’s patented PCT Platform in cancer research, biomarker discovery, and food safety, as well as in proteomic and molecular biology studies.

In 2018, a record number of scientific papers highlighting the advantages of PCT over competitive methods were published, authored by researchers in North America, Europe, and Asia. Importantly, a number of these papers were written by scientists considered by many in the life sciences as Key Opinion Leaders (“KOLs”) in their field. High quality papers authored by independent scientists - especially KOLs - and published in well-known, respected journals are an integral part of PBI’s marketing strategy.

Roxana McCloskey, PBI’s Global Director of Sales & Marketing, commented: “We know that scientists have a strong tendency to rely heavily on data and opinions from colleagues and other experts in their field. We therefore enhanced our marketing efforts during the second half of 2018 with a concerted effort to forward this large number of scientific publications to our base of existing and potential customers.We were pleased to see this effort result in increased interest and sales of our Barocycler instruments in 2018, which we believe will continue into 2019 as well.”

The 2018 publications were primarily in the following key areas.

Cancer Research

Six publications in cancer research reported the use of the PCT Platform to rapidly breakup tissue samples and release molecules for analysis. PCT’s ability to help reveal thousands of proteins from small diagnostic samples, such as cancer tissue biopsies extracted with tiny needles, could result in better understanding of patients’ cancers, disease progression, response to therapy, and treatment options. One paper proposed that the PCT Platform could be part of a method that has the potential to accelerate and strengthen protein analysis, improve cancer characterization, and provide clinically relevant information for diagnosis and treatment guidance in a timely manner.

Biomarker Discovery

In addition to cancer biomarker discovery, two papers reported the use of the PCT Platform in studies of biomarkers for cornea, lung and heart disease. Discovery of new biomarkers for early diagnosis, progression, and underlying pathway dysfunction is vital to help improve clinical outcomes. In addition, it was suggested that such biomarkers could serve as possible drug targets.

Food Safety

Four publications described the use PBI’s ultra-high pressure platforms to determine conditions forkilling certain bacteria in foods. Recent enhancements in the commercial feasibility of high-pressure processing (HPP) have been pivotal in the development of new methods for ensuring food safety, while preserving important sensory experience and quality factors. We believe that much of the data generated with PBI’s high pressure-based instruments will assist food safety researchers worldwide as they consider the use of pressure-based interventions for their microbiological studies.

Protein and Molecular Biology Studies

Several papers reported the use of PCT Platform for proteomic research. The proteome consists of all the proteins made or modified by an organism. Studies of proteins, using PBI’s high pressure systems, included protein structure, drug delivery, and diseasestates. The remaining papers covered a range of research including metabolomics, analytical biochemistry, and environmental biology. The papers published in 2018 show the value of PBI’s Platform as a general tool for basic research as well as a system for applied studies.

Richard T. Schumacher, President and CEO of PBI, said: “We are very pleased at both the number and wide range of the publications demonstrating the use of our PCT Platform. It is estimated that by 2022, the combined projected market sizes for cancer research, biomarker discovery, and proteomics and molecular biology could be in excess of $250 Billion, with the cancer biomarkers market alone projected to reach $150 Billion. High pressure processing of food is currently estimated to be a multi-billion dollar market. We believe that the credibility gained through scientific papers such as the more than 20 that were published in 2018, and the supportive data and new applications that the authors developed and presented in their publications, will enable PBI to better address these very large and growing markets.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired technology from BaroFold, Inc. (the “Barofold” technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

Bradford A. Young, Ph.D., MBA, Sr. VP & Chief Commercial Officer (508) 230-1829 (F)

SOURCE: Pressure BioSciences, Inc.

AP RADIO
Update hourly